Supreme Court Upholds Telehealth Access to Abortion Pill Amid Ongoing Legal and Political Threats

On Thursday the Supreme Court ruled that providers may continue mailing mifepristone and dispensing it through pharmacies while the Louisiana v. FDA case proceeds. The Court extended its stay of the 5th Circuit order that required in-person dispensing, preserving telehealth as a channel for medication abortion.

The Intercept

Since Dobbs v. Jackson (2022) ended the constitutional right to abortion, telehealth has become a primary delivery method for medication abortions. Conservatives have revived the 1873 Comstock Act—an anti-obscenity law—to argue that mailing abortion drugs is illegal, despite a 2022 DOJ memo stating the statute is unenforced and scholars deeming it unconstitutional. Project 2025 analysts have urged DOJ enforcement.

The Intercept

In 2023 roughly two-thirds of U.S. abortions were medication abortions. By 2025 more patients in total-ban states obtained abortions via telehealth than traveled out of state. The mifepristone-misoprostol regimen carries a serious-adverse-event risk under one percent, while maternal mortality from childbirth is about fourteen times higher. Over two decades of data confirm its safety.

The Intercept

Advocates called the ruling a temporary reprieve but warned the threat to mifepristone persists. Anna Bernstein of the Guttmacher Institute said the FDA’s safety review appears politically motivated and that the Trump-aligned administration may delay action until after the midterms. Republican legislators have urged courts to enforce the Comstock Act against mail-ordered mifepristone.

The Intercept

Justices Clarence Thomas and Samuel Alito dissented, calling the decision a “scheme” to sidestep Dobbs and reiterating that the Comstock Act bans mailing abortion drugs. Republican lawmakers and Project 2025 analysts have pressed for DOJ enforcement. Legal scholars argue the Act is unenforceable and violates First-Amendment precedent, and no clear timeline exists for the FDA’s safety review, leaving post-midterm enforcement uncertain.

The Intercept

• “The Comstock Act bans using ‘the mails’ to ship any ‘drug … for producing abortion,’” — Justice Clarence Thomas, dissent

The Intercept

• “We’re focusing on some pressing threats that are already ongoing,” — Anna Bernstein, principal federal policy adviser, Guttmacher Institute

The Intercept

• “This decision could have been the biggest blow to abortion access since the Dobbs decision,” — Claire Teylouni, Reproductive Equity Now

The Intercept

• “scheme” — Samuel Alito, dissent

The Intercept

The Louisiana v. FDA case will continue in lower courts, and the FDA’s safety review of mifepristone proceeds under Commissioner Kyle Diamantas, who has signaled a pro-life priority. Enforcement of the Comstock Act and midterm election dynamics could shape future access.

The Intercept